Skip to main content

Table 1 Characteristics of the rheumatoid arthritis patient cohorts

From: CD56+ monocytes have a dysregulated cytokine response to lipopolysaccharide and accumulate in rheumatoid arthritis and immunosenescence

Characteristics

All RA patients

Longitudinal etanercept study

 

(N= 75)

(N= 16)

Median age, years (range)

57.0 (23 to 83)

56.0 (41 to 66)

Female/male (n)

55/20

10/6

Median disease duration, years (range)

7.0 (1 to 57)

2 (1 to 13)

RF-positive (%)

77.0

68.8

Anti-CCP-positive (%)

75.8

93.8

Median CRP, mg/dl (range)

3.53 (0 to 113)

4.40 (0.5 to 21.1)

DMARDs (n)

  

  Methotrexate

42

13

  Azathioprine

1

0

  Leflunomide

4

1

  Anti-TNF

7

0

  Anti-TNF + MTX

2

0

  Abatacept

1

0

  Hydroxychloroquine + MTX

1

1

  Cyclosporin A

1

0

  Cyclosporin A + MTX

1

0

  Tocilizumab

1

0

  Rituximab

1

0

  Without

13

1

  1. aCCP, cyclic citrullinated peptide; CRP, C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumor necrosis factor.